Pasar al contenido principal

IDENTIFICAR LOS MECANISMOS CONVERGENTES ACTIVADOS POR LA HUNTINGTINA MUTADA Y LA FALTA DE VPS13A RESPONSABLES DE LA NEURODEGENERACION SELECTIVA DE LAS NEURONAS ESTRIATALES PAR

PID2020-119386RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Thalamic Foxp2 regulates output connectivity and sensory-motor impairments in a model of Huntington's Disease

  • Rodríguez-Urgellés, Ened
  • Casas-Torremocha, Diana
  • Sancho-Balsells, Anna
  • Ballasch, Iván
  • García-García, Esther
  • Miquel-Rio, Lluís
  • Manasanch, Arnau
  • Del Castillo, Ignacio
  • Chen, Wanqi
  • Pupak, Anika
  • Brito, Veronica
  • Tornero, Daniel
  • Rodríguez, Manuel J.
  • Bortolozzi, Analía
  • Sanchez-Vives, Maria V.
  • Giralt, Albert
  • Alberch, Jordi
Huntington's Disease (HD) is a disorder that affects body movements. Altered glutamatergic innervation of the striatum is a major hallmark of the disease. Approximately 30% of those glutamatergic inputs come from thalamic nuclei. Foxp2 is a transcription factor involved in cell differentiation and reported low in patients with HD. However, the role of the Foxp2 in the thalamus in HD remains unexplored., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. AG is a Ramón y Cajal fellow (RYC-2016–19466). This work was supported by grants from Ministerio de Ciencia e Innovación/ AEI/10.13039/501100011033/ and “FEDER”: AG: PID2021-122258OB-I00; MVSV: PID2020-112947RB-I00; AB: PID2019-105136RB-100; DT: PID2020-118120RB-I00; JA & MJR: PID2020-119386RB-100. Funded by H2020 Grant Agreement No. 945539 (Human Brain Project SGA3 to MVSV). IDIBAPS is funded by the CERCA program (Generalitat de Catalunya)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Age-stratified associations between severe mental illness, dementia, and ischemic stroke: findings from the PADRIS-PRESTO cohort

  • De Prisco, Michele
  • Oliva, Vincenzo
  • Sanchez-Valle, Raquel
  • Parellada, Eduard
  • Junque, Carme
  • Marti, Maria J.
  • Bortolozzi, Analía
  • Alberch, Jordi
  • Garrabou, Gloria
  • Sanchez-Vives, Maria V.
  • Giralt, Albert
  • Segura, Barbara
  • Lladó, Albert
  • Compta, Yaroslau
  • Radua, Joaquim
  • Vieta, Eduard
  • Hidalgo-Mazzei, Diego
  • Anmella, Gerard
People with severe mental illnesses (SMIs), including schizophrenia spectrum disorders (SSD), major depressive disorder (MDD), and bipolar disorder (BD), experience elevated rates of physical comorbidity and premature mortality. Dementia and ischemic stroke contribute substantially to this burden, yet age-specific patterns of these associations remain poorly characterized. To bridge this gap, we conducted a population-based cross-sectional study using the PADRIS-PRESTO cohort, integrating primary and specialized care records from the Catalan public health system (Spain). Adults with a lifetime SMI diagnosis were compared with controls without any psychiatric condition. Weighted age-stratified prevalence was calculated and logistic regression models estimated age-specific odds ratios (ORs) with 95% confidence intervals (CIs), adjusting for socioeconomic status and medical comorbidity burden. Among 694,086 participants, 176,870 had an SMI diagnosis. Dementia prevalence was 3.49% (range, 0.33% at ages 20-29 to 39.51% at 90-99 years) in SMIs and 0.36% (0.02%-17.7%) in controls. Ischemic stroke prevalence was 5.3% (0.22%-16.4%) in SMIs and 2.75% (0.08%-14.67%) in controls. The ORs between SMI and dementia were significant across all age groups, with the strongest association observed at younger ages (OR = 23.21, 95% CIs = 13.74-39.19 at 30-39 years). Elevated ORs for stroke persisted up to 70-79 years, peaking at 40-49 years (OR = 2.99, 95% CIs = 2.63-3.41). Patterns were consistent across SMI subtypes. These findings highlight the need for earlier and more systematic neurological and cardiometabolic screening and management within psychiatric care and support policies that recognize SMIs as risk factors for vascular diseases and dementia., Michele De Prisco is supported by the Translational Research Programme for Brain Disorders, IDIBAPS. Vincenzo Oliva thanks the support of the Spanish Ministry of Science, Innovation and Universities financed by the Instituto de Salud Carlos III (ISCIII) and co-financed by the European Social Fund+ (ESF+) (CM24/00143, MV25/00042). Carme Junque thanks the Spanish Ministry of Economy and Competitiveness (MINECO PID2020-114640GB-I00/ and PID2023-146932NB-I00 financed by MICIU/AEI/ 110.13039/5011000111033/FEDER, UE); Generalitat de Catalunya (SGR 2021SGR00801); María de Maeztu Unit of Excellence (Institute of Neurosciences, University of Barcelona) CEX2021001159-M, Ministry of Science and Innovation; and La Marato 202225-31358/U/2022. Analia Bortolozzi thanks the Spanish Ministry of Economy and Competitiveness (MCIU/AEI/FEDER, UE grant PID2022-141700OB-I00, MCIN/AEI/10.13039/501100011033); La Marató de TV3 Foundation 202207-30; and Caixa Research Health - HR25-00556. Jordi Alberch is supported by a grant from Ministerio de Ciencia e Innovación/AEI/https://doi.org/10.13039/501100011033/ and “FEDER” (PID2024-157024OB-I00). Gloria Garrabou is supported by The Catalan Government (2021-SGR-01423), and Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III (PI24/00428) and CIBERER, both initiatives of ISCIII and FEDER, co-funded by the European Union. Maria V. Sanchez-Vives is funded by the European Union (ERC, NEMESIS, project number 101071900). Albert Giralt is supported by a grant from Ministerio de Ciencia e Innovación/AEI/https://doi.org/10.13039/501100011033/ and “FEDER” (PID2020-119386RB-I00). Barbara Segura thanks the Spanish Ministry of Economy and Competitiveness (PID2023-146932NB-I00 financed by MICIU/AEI/ 110.13039/5011000111033/FEDER, UE); Generalitat de Catalunya (SGR 2021SGR00801); María de Maeztu Unit of Excellence (Institute of Neurosciences, University of Barcelona) CEX2021001159-M, Ministry of Science and Innovation; and La Marato 202225-31358/U/2022. Joaquim Radua thanks the support of the Spanish Ministry of Science, Innovation and Universities (CPII19/00009, PI22/00261, PI25/01463) integrated into the Plan Nacional de I + D+I and co-financed by the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) and the Instituto de Salud Carlos III; and the Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2021-SGR-01128). Eduard Vieta thanks the support of the Spanish Ministry of Science, Innovation and Universities (PI21/00787, PI24/00432) integrated into the Plan Nacional de I+D+I and co-financed by the Instituto de Salud Carlos III -Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); the Generalitat de Catalunya and Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2021 SGR 01128), CERCA Programme, Generalitat de Catalunya; La Marató-TV3 Foundation grants 202234-30; the European Union Horizon 2020 research and innovation program (H2020-EU.3.1.1. - Understanding health, wellbeing and disease, H2020-EU.3.1.3. Treating and managing disease: Grant 945151, HORIZON.2.1.1 - Health throughout the Life Course: Grant 101057454 and EIT Health (EDIT-B project). Diego Hidalgo-Mazzei gratefully acknowledges the support of the Spanish Ministry of Health, Instituto de Salud Carlos III (PI049759) and the Pons-Bartran Legacy grant 2024 (FCRB_IPB1_2024). Gerard Anmella thanks the support of the Spanish Ministry of Science, Innovation and Universities financed by the Instituto de Salud Carlos III (ISCIII) and co-financed by the European Social Fund+ (ESF+) (JR23/00050, MV22/00058, CM21/00017); the ISCIII (PI24/00584, PI24/01051, PI21/00340, PI21/00169); the Milken Family Foundation (PI046998); the Fundació Clínic per a la Recerca Biomèdica (FCRB) - Pons Bartan 2020 grant (PI04/6549), the Sociedad Española de Psiquiatría y Salud Mental (SEPSM); the Fundació Vila Saborit; the Societat Catalana de Psiquiatria i Salut Mental (SCPiSM); and the Translational Research Programme for Brain Disorders, IDIBAPS. IG has received support from the Spanish Ministry of Science, Innovation and Universities (MCIN) (PI23/00822) integrated into the Plan Nacional de I+D+I and cofinanced by the ISCIII-Subdirección General de Evaluación and European Union (FEDER, FSE, Next Generation EU/Plan de Recuperación Transformación y Resiliencia_PRTR); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); and Generalitat de Catalunya and Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2021 SGR 01128), CERCA Programme / Generalitat de Catalunya as well as the Fundació Clínic per la Recerca Biomèdica (Pons Bartran 2022-FRCB_PB1_2022)., Peer reviewed
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

RTP801 interacts with the tRNA ligase complex and dysregulates its RNA ligase activity in Alzheimer's disease

  • Campoy-Campos, Genís
  • Solana-Balaguer, Júlia
  • Guisado-Corcoll, Anna
  • Chicote-González, Almudena
  • García-Segura, Pol
  • Pérez-Sisqués, Leticia
  • Gabriel Torres, Adrián
  • Canal, Mercè
  • Molina-Porcel, Laura
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
  • Pouplana, Lluís Ribas de
  • Alberch, Jordi
  • Martí, Eulàlia
  • Giralt, Albert
  • Pérez-Navarro, Esther
  • Malagelada, Cristina
RTP801/REDD1 is a stress-responsive protein overexpressed in neurodegenerative diseases such as Alzheimer's disease (AD) that contributes to cognitive deficits and neuroinflammation. Here, we found that RTP801 interacts with HSPC117, DDX1 and CGI-99, three members of the tRNA ligase complex (tRNA-LC), which ligates the excised exons of intron-containing tRNAs and the mRNA exons of the transcription factor XBP1 during the unfolded protein response (UPR). We also found that RTP801 modulates the mRNA ligase activity of the complex in vitro since RTP801 knockdown promoted XBP1 splicing and the expression of its transcriptional target, SEC24D. Conversely, RTP801 overexpression inhibited the splicing of XBP1. Similarly, in human AD postmortem hippocampal samples, where RTP801 is upregulated, we found that XBP1 splicing was dramatically decreased. In the 5xFAD mouse model of AD, silencing RTP801 expression in hippocampal neurons promoted Xbp1 splicing and prevented the accumulation of intron-containing pre-tRNAs. Finally, the tRNA-enriched fraction obtained from 5xFAD mice promoted abnormal dendritic arborization in cultured hippocampal neurons, and RTP801 silencing in the source neurons prevented this phenotype. Altogether, these results show that elevated RTP801 impairs RNA processing in vitro and in vivo in the context of AD and suggest that RTP801 inhibition could be a promising therapeutic approach., This work was supported in part by the grants SAF2017-88812-R and PID2020-119236RB-I00 by MICIU/AEI/10.13039/501100011033 and by 'ERDF A way of making Europe' (from CM), PID2020-119386RB-I00 (from JA), PID2019-106447RB-I00 (from EP-N), PID2020- 113953RB-I00 (from EM), and PID2019-110356RB-I00 (from JF-I and ES).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Motor skill learning modulates striatal extracellular vesicles' content in a mouse model of Huntington's disease

  • Solana-Balaguer, Júlia
  • García-Segura, Pol
  • Campoy-Campos, Genís
  • Chicote-González, Almudena
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
  • Pérez-Navarro, Esther
  • Masana, Mercè
  • Alberch, Jordi
  • Malagelada, Cristina
Huntington's disease (HD) is a neurological disorder caused by a CAG expansion in the Huntingtin gene (HTT). HD pathology mostly affects striatal medium-sized spiny neurons and results in an altered cortico-striatal function. Recent studies report that motor skill learning, and cortico-striatal stimulation attenuate the neuropathology in HD, resulting in an amelioration of some motor and cognitive functions. During physical training, extracellular vesicles (EVs) are released in many tissues, including the brain, as a potential means for inter-tissue communication. To investigate how motor skill learning, involving acute physical training, modulates EVs crosstalk between cells in the striatum, we trained wild-type (WT) and R6/1 mice, the latter with motor and cognitive deficits, on the accelerating rotarod test, and we isolated their striatal EVs. EVs from R6/1 mice presented alterations in the small exosome population when compared to WT. Proteomic analyses revealed that striatal R6/1 EVs recapitulated signaling and energy deficiencies present in HD. Motor skill learning in R6/1 mice restored the amount of EVs and their protein content in comparison to naïve R6/1 mice. Furthermore, motor skill learning modulated crucial pathways in metabolism and neurodegeneration. All these data provide new insights into the pathogenesis of HD and put striatal EVs in the spotlight to understand the signaling and metabolic alterations in neurodegenerative diseases. Moreover, our results suggest that motor learning is a crucial modulator of cell-to-cell communication in the striatum., Ministerio de Ciencia e Innovación (#FPU18/00194, FPU21/02928, PID2020-119236RB-I00, PID2019-106447RB-I00, PID2021-124896OA-I000, PID2020-119386RB-I00, SAF2017-88812-R). Agència de Gestió d'Ajuts Universitaris i de Recerca (FI-B-00378). Michael J. Fox Foundation for Parkinson's Research (MJFF-000858, MJFF-000858). Horizon 2020 Framework Programme (863214).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Alterations of the IKZF1-IKZF2 tandem in immune cells of schizophrenia patients regulate associated phenotypes

  • Ballasch, Iván
  • López-Molina, Laura
  • Galán-Ganga, Marcos
  • Sancho-Balsells, Anna
  • Rodríguez-Navarro, Irene
  • Borràs-Pernas, Sara
  • Rabadán, M. Ángeles
  • Chen, Wanqi
  • Pastó-Pellicer, Carlota
  • Flotta, Francesca
  • Maoyu, Wang
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
  • Aguilar, Ruth
  • Dobaño, Carlota
  • Egri, Natalia
  • Hernández, Carla
  • Alfonso, Miqueu
  • Juan, Manel
  • Alberch, Jordi
  • Toro, Daniel del
  • Arranz, Belén
  • Canals, Josep M.
  • Giralt, Albert
Schizophrenia is a complex multifactorial disorder and increasing evidence suggests the involvement of immune dysregulations in its pathogenesis. We observed that IKZF1 and IKZF2, classic immune-related transcription factors (TFs), were both downregulated in patients' peripheral blood mononuclear cells (PBMCs) but not in their brain. We generated a new mutant mouse model with a reduction in Ikzf1 and Ikzf2 to study the impact of those changes. Such mice developed deficits in the three dimensions (positive-negative-cognitive) of schizophrenia-like phenotypes associated with alterations in structural synaptic plasticity. We then studied the secretomes of cultured PBMCs obtained from patients and identified potentially secreted molecules, which depended on IKZF1 and IKZF2 mRNA levels, and that in turn have an impact on neural synchrony, structural synaptic plasticity and schizophrenia-like symptoms in in vivo and in vitro models. Our results point out that IKZF1-IKZF2-dependent immune signals negatively impact on essential neural circuits involved in schizophrenia., This work was supported by grants from Ministerio de Ciencia e Innovación/AEI/https://doi.org/10.13039/501100011033/ and “FEDER” to A.G.: PID2021-122258OB-I00 and to J.A.: PID2020-119386RB-100 and from Instituto de Salud Carlos III (ISCIII): PI17/00246 to B.A. Our technician Ana López, was supported by a María de Maeztu Unit of Excellence (Institute of Neurosciences, University of Barcelona, CEX2021-001159-M, Ministry of Science and Innovation). The project that gave rise to these results received the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is LCF/BQ/DR21/11880016 to M.G.-G.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Photoactivated adenylyl cyclase in cortical astrocytes promotes synaptic potentiation and reveals alterations in Huntington's disease

  • Sitjà-Roqueta, Laia
  • Ngum, Neville M.
  • Zherebtsov, Evgenii A.
  • Küçükerden, Melike
  • Givehchi, Maryam
  • Bova, Valentina
  • Delicata, Francis
  • Anaya-Cubero, Elena
  • Santamaría Martínez, Enrique
  • Fernández Irigoyen, Joaquín
  • Conde-Berriozabal, Sara
  • Castañé, Anna
  • Sokolovski, Sergei
  • Rafailov, Edik
  • Rodríguez, Manuel J.
  • Alberch, Jordi
  • Dalkara, Deniz
  • Möglich, Andreas
  • Bykov, Alexander
  • Meglinski, Igor
  • Parri, H. Rheinallt
  • Masana, Mercè
Coordinated neuron-astrocyte interactions are crucial for synaptic plasticity and brain function. Cyclic adenosine monophosphate (cAMP) pathways have a key role in modulating plasticity and are disrupted in neurodegenerative diseases. Yet, the role of astrocytic cAMP remains unclear. We addressed this by expressing the photoactivatable adenylyl cyclase DdPAC in cortical astrocytes, enabling cAMP synthesis under red light stimulation. Using electrophysiological and comprehensive proteomic analyses, we determined its effects in wild-type mice. The modulation of astrocytic cAMP triggered long-term synaptic potentiation and rapidly induced the phosphorylation of proteins involved in synaptic transmission, including PKA. In Huntington's Disease (HD) models, DdPAC activation in cortical astrocytes differentially enhanced brain hemodynamics and induced motor learning, while specifically increasing grooming and impairing coordination in HD mice. Thus, we reveal a mechanism of astrocyte-driven plasticity mediated by cAMP elevation and underscore the alterations in astrocytic cAMP signaling associated with HD., This research is part of the NEUROPA and GlioLight project. The NEUROPA Project has received funding from the European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No. 863214. The GlioLight project has received funding from the European Innovation Council under grant Agreement 101129705. The Aston Institute for Membrane Excellence (AIME) is funded by UKRI’s Research England as part of their Expanding Excellence in England (E3) fund. MK is funded by Horizon Europe Marie Skłodowska-Curie Actions (101104889). This study was supported by grants from the Ministerio de Ciencia y Innovación (Spain) y la Agencia Estatal de Investigación, under projects CNS2023-143999 (MM.), PID2021-124896OA-I00 (M.M.), and no. PID2020-119386RB-I00 (J.A. and M.J.R.); Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades and European Regional Development Fund (ERDF) [CIBERNED, to J.A.], Spain. Also, the project has been supported by María de Maeztu Unit of Excellence (CEX2021-001159), the Institute of Neurosciences of the University of Barcelona, Ministry of Science, Innovation, and Universities, and the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, Catalunya) (2021SGR01086).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

RTP801 mediates transneuronal toxicity in culture via extracellular vesicles

  • Solana-Balaguer, Júlia
  • Martín-Flores, Núria
  • García-Segura, Pol
  • Campoy-Campos, Genís
  • Pérez-Sisqués, Leticia
  • Chicote-González, Almudena
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
  • Pérez-Navarro, Esther
  • Alberch, Jordi
  • Malagelada, Cristina
Extracellular vesicles (EVs) play a crucial role in intercellular communication, participating in the paracrine trophic support or in the propagation of toxic molecules, including proteins. RTP801 is a stress-regulated protein, whose levels are elevated during neurodegeneration and induce neuron death. However, whether RTP801 toxicity is transferred trans-neuronally via EVs remains unknown. Hence, we overexpressed or silenced RTP801 protein in cultured cortical neurons, isolated their derived EVs (RTP801-EVs or shRTP801-EVs, respectively), and characterized EVs protein content by mass spectrometry (MS). RTP801-EVs toxicity was assessed by treating cultured neurons with these EVs and quantifying apoptotic neuron death and branching. We also tested shRTP801-EVs functionality in the pathologic in vitro model of 6-Hydroxydopamine (6-OHDA). Expression of RTP801 increased the number of EVs released by neurons. Moreover, RTP801 led to a distinct proteomic signature of neuron-derived EVs, containing more pro-apoptotic markers. Hence, we observed that RTP801-induced toxicity was transferred to neurons via EVs, activating apoptosis and impairing neuron morphology complexity. In contrast, shRTP801-EVs were able to increase the arborization in recipient neurons. The 6-OHDA neurotoxin elevated levels of RTP801 in EVs, and 6-OHDA-derived EVs lost the mTOR/Akt signalling activation via Akt and RPS6 downstream effectors. Interestingly, EVs derived from neurons where RTP801 was silenced prior to exposing them to 6-OHDA maintained Akt and RPS6 transactivation in recipient neurons. Taken together, these results suggest that RTP801-induced toxicity is transferred via EVs, and therefore, it could contribute to the progression of neurodegenerative diseases, in which RTP801 is involved., Supported in part by grants from Ministerio de Ciencia e Innovación /AEI/10.13039/501100011033/ and ‘FEDER’: SAF2017-88812-R and PID2020-119236RB-I00, from CM; PID2020-119386RB-I00 from JA and PID2019-106447RB-I00 from EP-N. JS-B was supported by a FPU grant from the Spanish Ministry of Science and Innovation (grant #FPU18/00194). NM-F was supported by a FPI grant from the Spanish Ministry of Science and Innovation (grant IBES-2015-072727). PG-S was supported by a FPU grant from the Spanish Ministry of Science and Innovation (grant #FPU21/02928). GC-C was funded by a FI-2021 grant from the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) (grant #FI-B-00378). AC-G was supported by a Michael J. Fox Foundation grant (MJFF-000858). Supported also bythe crowdfunding campaign ‘SOS recerca en Parkinson’ via Goteo.org and Portal d’Avall, S.L.